Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	To study and compare efficacy of: <br/ >1.Vitamin D3 with Magnesium Glycinate therapy. <br/ >2.Cilnidipine + Telmisartan therapy. <br/ >3.Vitamin D3 + Magnesium Glycinate + Cilnidipine + Telmisartan therapy. <br/ >for reduction in severity of COVID-19 disease using non-invasive measurement of Arterial Stiffness as a clinical marker <br/ >Timepoint: The Pulse wave velocity in both groups will be evaluated on Day 1; 3; 5 and at discharge or day 7 or on the day of clinical deterioration whichever is earlier.	To study and compare efficacy of: <br/ >1.Vitamin D3 with Magnesium Glycinate therapy. <br/ >2.Cilnidipine + Telmisartan therapy. <br/ >3.Vitamin D3 + Magnesium Glycinate + Cilnidipine + Telmisartan therapy. <br/ >for reduction in severity of COVID-19 disease using non-invasive measurement of Arterial Stiffness as a clinical marker <br/ >Timepoint: The Pulse wave velocity in both groups will be evaluated on Day 1; 3; 5 and at discharge or day 7 or on the day of clinical deterioration whichever is earlier.
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
May 27, 2021, 12:45 a.m.	oms	To study and compare efficacy of: <br/ >1.Vitamin D3 with Magnesium Glycinate therapy. <br/ >2.Cilnidipine + Telmisartan therapy. <br/ >3.Vitamin D3 + Magnesium Glycinate + Cilnidipine + Telmisartan therapy. <br/ >for reduction in severity of COVID-19 disease using non-invasive measurement of Arterial Stiffness as a clinical marker <br/ >Timepoint: The Pulse wave velocity in both groups will be evaluated on Day 1; 3; 5 and at discharge or day 7 or on the day of clinical deterioration whichever is earlier.	To study and compare efficacy of: <br/ >1.Vitamin D3 with Magnesium Glycinate therapy. <br/ >2.Cilnidipine + Telmisartan therapy. <br/ >3.Vitamin D3 + Magnesium Glycinate + Cilnidipine + Telmisartan therapy. <br/ >for reduction in severity of COVID-19 disease using non-invasive measurement of Arterial Stiffness as a clinical marker <br/ >Timepoint: The Pulse wave velocity in both groups will be evaluated on Day 1; 3; 5 and at discharge or day 7 or on the day of clinical deterioration whichever is earlier.